The June issue of GEN doubles your learning opportunities. It has two articles on multiomics (one on emerging technologies; one on clinical applications), and it has two lists of top gene editing therapy companies (one for public companies; one for private companies). The June issue also has two articles on upstream bioprocessing. Both emphasize process intensification technologies that establish pairs: on one side, there is the modeled; on the other, the modeler. (The logical extreme is the digital twin.) Similar pairings of the virtual and the real crop up elsewhere in the issue. For example, there’s an article on AI-assisted drug development that juxtaposes target space with computational space. Also, there’s an editorial about the need to pair AI-derived findings with validating information from wet-lab experiments. Finally, there are articles about proliferating CRISPR gene editing technologies and microbiome therapeutics. Lots of them. (Not everything comes in pairs!)